Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: Eli Lilly and Company
Summary
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Official title: Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-03
Completion Date
2032-12
Last Updated
2026-03-24
Healthy Volunteers
No
Interventions
Pirtobrutinib
Administered orally
Idelalisib
Administered orally
Locations (50)
Mitchell Cancer Institute
Mobile, Alabama, United States
Arizona Oncology Associates, P.C. - HOPE
Tucson, Arizona, United States
Cancer Specialists, LLC
Jacksonville, Florida, United States
Minnesota Oncology Hematology, P.A.
Coon Rapids, Minnesota, United States
Cayuga Cancer Center
Ithaca, New York, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States
Oncology Hematology Care Inc
Cincinnati, Ohio, United States
Texas Oncology - Paris
Fort Worth, Texas, United States
US Oncology - Texas Oncology
Kyle, Texas, United States
Liverpool Hospital
Liverpool, Australia
The Alfred Hospital
Melbourne, Australia
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, Austria
AZ Delta
Roeselare, Belgium
Princess Margaret Cancer Centre - University Health Network
Toronto, Canada
Xuanwu Hospital Capital Medical University
Beijing, China
Sun Yat-sen University Cancer Center
Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, China
Gansu Provincial Cancer Hospital
Lanzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Taizhou Hospital of Zhejiang Province
Taizhou, China
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, China
Henan Cancer Hospital
Zhengzhou, China
University Hospital Center Zagreb
Zagreb, Croatia
Centre Henri Becquerel
Rouen, France
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
Budapest, Hungary
Debreceni Egyetem
Debrecen, Hungary
St. James's Hospital
Dublin, Ireland
Beaumont Hospital
Dublin, Ireland
Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
Presidio Ospedaliero Papardo
Messina, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
Perugia, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Tel Aviv Sourasky Medical Center
Tel Aviv, Italy
Azienda Ospedaliera S. Maria Di Terni
Terni, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma
Verona, Italy
Tokai University Hospital
Isehara, Japan
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza
Brzozów, Poland
Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy
Bydgoszcz, Poland
Pratia Onkologia Katowice
Katowice, Poland
Instytut Hermatologii I Transfuzjologii
Warsaw, Poland
Hospital Universitario Marques De Valdecilla
Santander, Spain
Hospital Universitario Virgen Del Rocio
Seville, Spain
Castle Hill Hospital
Hull, United Kingdom
St James's University Hospital
Leeds, United Kingdom
GenesisCare
Newmarket, United Kingdom